9.JPG)
Global AI-Enabled Drug Discovery and Clinical Trials Market Size is valued at USD 883.9 Million in 2024 and is predicted to reach USD 9321.5 Million by the year 2034 at a 26.7 % CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- Technology advancements enhance the ability to analyze drug discovery processes, which is driving the AI-enabled drug discovery and clinical trials market.
- Precision medicine's personalized treatment approach increases demand for AI in drug discovery and clinical trials.
- North America dominated the market and accounted for a global revenue share in 2024.
- The key challenge for AI-based clinical trial solutions for the patient matching market is the high initial investment required.
AI-Enabled Drug Discovery and Clinical Trials are expected to gain promiscuous popularity over the coming years due to a rapid increase in the use of AI worldwide and its increasing scope of application in multiple industry verticals. Artificial intelligence technology is advancing rapidly, and continuous technological advancements are expected to boost AI-Enabled Drug Discovery and Clinical Trials market potential. The increasing digitization of the healthcare industry will also majorly propel AI-Enabled Drug Discovery and Clinical Trials across the world through 2031. Rising research and development activity will also help the AI-Enabled Drug Discovery and Clinical Trials market gain the expected impetus in the global marketplace through 2031.
However, the high costs associated with AI-Enabled Drug Discovery and Clinical Trials are expected to have a negative impact on the global AI-Enabled Drug Discovery and Clinical Trials market growth. The AI-Enabled Drug Discovery and Clinical Trials market experienced an increase in demand in the COVID-19 pandemic to fast track development of vaccines, and this trend set the stage for future market growth and will enhance AI-Enabled Drug Discovery and Clinical Trials market performance over the forecast period.
Market Segmentation:
The AI-Enabled Drug Discovery and Clinical Trials market is segmented on the basis of product and application. Based on the component scope, the market is segmented into solutions and services. By application, the market is segmented into Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, and Biomarker Research. By therapeutic application, the market is segmented into Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorders, Metabolic Diseases, Immunologic Diseases, and Infectious Diseases. By end-users, the market is segmented into Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers.
Based On Therapeutic Application, The Oncology Segment Dominates
The incidence of cancer has risen substantially over the past few years, and this has bolstered demand for oncology across the world. Increasing investments in oncology research and development are expected to boost AI-Enabled Drug Discovery and Clinical Trials market potential over the forecast period. The oncology segment is expected to be the most lucrative application segment over the forecast period.
Biopharmaceutical Industry To Lead Growth
The biopharmaceutical industry has taken notable strides ahead over the past few years, and this trend is rife over the forecast period as well. The rising number of biopharmaceutical companies across the world and increasing investments in research activity coupled with supportive government initiatives are expected to provide highly lucrative opportunities for AI-Enabled Drug Discovery and Clinical Trials market growth through 2031.
The North America AI-Enabled Drug Discovery And Clinical Trials Market Holds A Dominant Outlook In The Region.
Global AI-Enabled Drug Discovery and Clinical Trials market in North America is estimated to dominate the forecast period due to the existence of strong healthcare infrastructure. Increasing investment on R&D activities sponsored by governments in this area is likely to be a major driver through 2030. Increasing adoption of technology in healthcare, favorable reimbursement policies, the surge in chronic diseases, rising incidence of cancers, and increasing demand for better diagnostics and treatment are other factors that are anticipated to propel the AI-Enabled Drug Discovery and Clinical Trials market growth over the forecast period. The United States and Canada are expected to lead the market growth in this region through 2031.
Recent Developments:
- In October 2021, Ardigen, a world-leading AI-driven drug discovery company, partnered with the Polish National Centre for Research and Development to fund groundbreaking technology. This collaboration aims to revolutionize the discovery of microbiome-based biomarkers in oncology.
Competitive Landscape
Some Major Key Players In The AI-Enabled Drug Discovery and Clinical Trials Market:
- Accutar Biotechnology Inc.,
- AiCure,
- Ardigen,
- Atomwise Inc.,
- Benevolent AI,
- Berg,
- Berkeley Lights,
- BioAge Labs,
- Biovista,
- C4X Discovery Holdings Plc,
- Clinithink Ltd,
- Cloud Pharmaceuticals,
- Cyclica Inc.,
- CytoReason,
- Concerto Health AI.,
- Deep Genomics Inc.,
- DeepThink Health Inc.,
- Envisagenics, Inc.,
- Exscientia Limited,
- e-therapeutics plc,
- GNS Healthcare,
- Insilico Medicine,
- Lantern Pharma Inc.,
- Medable, Inc.,
- Mind the Byte,
- NuMedii, Inc,
- Nuritas, Ltd.,
- Owkin, Inc.,
- Recursion Pharmaceuticals, Inc.,
- Schrödinger, LLC,
- Symphony Innovation, LLC,
- TARA Biosystems, Inc.,
- twoXAR, Incorporated,
- Verge Analytics, Inc.,
- Winterlight Labs Inc.,
- WuXi Nextcode Genomics,
- XtalPi Inc.,
- Other Prominent Players
AI-Enabled Drug Discovery and Clinical Trials Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 883.9 Million |
|
Revenue Forecast In 2034 |
USD 9321.5 Million |
|
Growth Rate CAGR |
CAGR of 26.7% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Component Scope, By Application, By Therapeutic Application, By End-Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Biogas Products Ltd., CNG Services Ltd., Cryon Purr, Envi Tec Biogas AG, ETW Energietechnik GmbH, Future Biogas Ltd., Gasline, Gasrec Ltd, Gazasia Ltd., Green Gas Certification, JV Energe, Magne Gas, MemfoACT, Nordsol, ORBITA, Planet Biogas Global Gm, Schmack Carbotech GmbH, Southern California Gas Compa, VERBIO. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
